335 related articles for article (PubMed ID: 32077550)
1. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
Jiang S; Liang H; Liu Z; Zhao S; Liu J; Xie Z; Wang W; Zhang Y; Han B; He J; Liang W
Oncologist; 2020 May; 25(5):e870-e874. PubMed ID: 32077550
[TBL] [Abstract][Full Text] [Related]
2. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
3. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
4. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
6. Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.
Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Cancer Med; 2022 Feb; 11(4):1081-1087. PubMed ID: 34939373
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
8. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
Shen Y; Lu J; Hu F; Qian J; Zhang X; Zhong R; Zhong H; Chu T; Han B
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1417-1424. PubMed ID: 35482076
[TBL] [Abstract][Full Text] [Related]
9. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
10. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.
He Z; Liu J; Ma Y; Jiang H; Cui Z; Wang G; Wu Y; Liu J; Cai X; Qian J; Huang J; Zhang H; Li H
Cancer Manag Res; 2021; 13():6101-6111. PubMed ID: 34377028
[TBL] [Abstract][Full Text] [Related]
12. Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.
Cheng Y; Wang Q; Li K; Shi J; Han B; Wu L; Chen G; He J; Wang J; Qin H; Li X
Cancer Innov; 2023 Jun; 2(3):181-190. PubMed ID: 38089404
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Shi J; Chen G; Wang H; Wang X; Han B; Li K; Wang Q; Zhang L; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Liu Z
Thorac Cancer; 2021 Sep; 12(17):2345-2351. PubMed ID: 34273139
[TBL] [Abstract][Full Text] [Related]
15. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
17. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L; He Z; Yang S; Tang H; Wu Y; Li S; Han B; Li K; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Sun Y; Wang Q
Transl Lung Cancer Res; 2019 Oct; 8(5):575-583. PubMed ID: 31737494
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Zhao Y; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Yamaguchi F; Breadner D; Nagano T; Tanaka F; Husain H; Li K; Han B
Transl Lung Cancer Res; 2022 May; 11(5):776-785. PubMed ID: 35693290
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yu G; Shen Y; Xu X; Zhong F
PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Zhang W; Zhang C; Yang S; Chen Q; Wang C; Guo Q
Future Oncol; 2021 Nov; 17(31):4091-4099. PubMed ID: 34254526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
